| Management of hemolytic uremic syndrome. | |
| | |
MedLine Citation:
|
PMID: 22284541 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
2011 has been a special year for hemolytic uremic syndrome (HUS): on the one hand, the dramatic epidemic of Shiga toxin producing E. coli -associated HUS in Germany brought the disease to the attention of the general population, on the other hand it has been the year when eculizumab, the first complement blocker available for clinical practice, was demonstrated as the potential new standard of care for atypical HUS. Here we review the therapeutic options presently available for the various forms of hemolytic uremic syndrome and show how recent knowledge has changed the therapeutic approach and prognosis of atypical HUS. |
| | |
Authors:
|
Chantal Loirat; Jeffrey Saland; Martin Bitzan |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-25 |
Journal Detail:
|
Title: Presse medicale (Paris, France : 1983) Volume: - ISSN: 0755-4982 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8302490 Medline TA: Presse Med Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2012 Elsevier Masson SAS. All rights reserved. |
Affiliation:
|
Assistance publique-Hôpitaux de Paris, Hôpital Robert-Debré, Nephrology Department, 75019 Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Stress and puberty-related hormone reactivity, negative emotionality, and parent-adolescent relation...
Next Document: Autonomic nervous system as a source of biomarkers in Parkinson's disease.